Inhibitors for protein kinases may ultimately constitute a novel family of medicinally active agents. Unfortunately, the challenges associated with the acquisition of inhibitors for the enzyme targets are unlike any that have ever been encountered in medicinal chemistry. Protein kinases pose a variety of obstacles in terms of inhibitor design, nearly all of which deal with, in one fashion or another, the issue of specificity. The principal investigator has recently discovered that even closely related protein kinases can be distinguished by differences in their active site substrate specificity Based upon these differences a series of kinase specific/selective inactivators/inhibitors has been created. All of these substrates, inhibitors, and inactivators are peptide-based species that interact with the protein-binding region of the active site. As a consequence, these compounds d not suffer from the severe disadvantages associated with inhibitors directed t the ATP-binding region. The purpose of the present proposal is to translate th principal investigator's promising in vitro results into compounds that function under in vivo conditions. The focus of the present proposal continues to be the ACG subfamily of protein kinases. Is it possible to develop both selective and potent inhibitors for th members of this kinase family, including individual isoforms? The principal investigator has found that appending non-amino acid residues to active site-directed peptides can dramatically enhance PKA affinity. The principal investigator will employ an analogous approach using two different types of chemical libraries to identify compounds exhibiting the requisite inhibitory traits for all members of the ACG subfamily. Although the active site-directed peptide inhibitors can establish whether a particular protein kinase is a member of a specific signaling pathway, they will not provide information concerning when and where the kinase is active, so a series of caged inhibitor will be developed for that purpose. Can protein kinase activity be assayed in direct, continuous, and highly sensitive fashion? The principal investigator has developed such a continuous assay for PKC. Analogous assays will be developed for the other members of the ACG family. Can in vivo assays be developed for protein kinases? Issues related to the direct visualization of protein kinase activity in the cell, including fluorophore design and sensitivity to intracellular phsophatases and proteinases will be examined.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
2R01GM045989-08
Application #
2612925
Study Section
Biochemistry Study Section (BIO)
Project Start
1991-04-01
Project End
2002-03-31
Budget Start
1998-04-01
Budget End
1999-03-31
Support Year
8
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Albert Einstein College of Medicine
Department
Biochemistry
Type
Schools of Medicine
DUNS #
009095365
City
Bronx
State
NY
Country
United States
Zip Code
10461
Sharma, Vyas; Wang, Qunzhao; Lawrence, David S (2008) Peptide-based fluorescent sensors of protein kinase activity: design and applications. Biochim Biophys Acta 1784:94-9
Shang, Limin; Kwon, Young-Guen; Nandy, Sandip et al. (2003) Catalytic and regulatory domains of doublecortin kinase-1. Biochemistry 42:2185-94
Arancio, O; Antonova, I; Gambaryan, S et al. (2001) Presynaptic role of cGMP-dependent protein kinase during long-lasting potentiation. J Neurosci 21:143-9
Yan, X; Curley, K; Lawrence, D S (2000) The specificity of the protein kinase C alpha, betaII and gamma isoforms as assessed by an unnatural alcohol-appended peptide library. Biochem J 349 Pt 3:709-15
White, R R; Kwon, Y G; Taing, M et al. (1998) Definition of optimal substrate recognition motifs of Ca2+-calmodulin-dependent protein kinases IV and II reveals shared and distinctive features. J Biol Chem 273:3166-72
Lev-Ram, V; Jiang, T; Wood, J et al. (1997) Synergies and coincidence requirements between NO, cGMP, and Ca2+ in the induction of cerebellar long-term depression. Neuron 18:1025-38
Werner, D S; Lee, T R; Lawrence, D S (1996) Is protein kinase substrate efficacy a reliable barometer for successful inhibitor design? J Biol Chem 271:180-5
Wood, J S; Yan, X; Mendelow, M et al. (1996) Precision substrate targeting of protein kinases. The cGMP- and cAMP-dependent protein kinases. J Biol Chem 271:174-9
Yan, X; Corbin, J D; Francis, S H et al. (1996) Precision targeting of protein kinases. An affinity label that inactivates the cGMP- but not the cAMP-dependent protein kinase. J Biol Chem 271:1845-8
Srinivasan, J; Koszelak, M; Mendelow, M et al. (1995) The design of peptide-based substrates for the cdc2 protein kinase. Biochem J 309 ( Pt 3):927-31

Showing the most recent 10 out of 17 publications